A fibrin antibody binding to fibronectin induces potent inhibition of angiogenesis

Summary

Antiserum from rabbits immunised with pure human fibrinogen was affinity purified on immobilised fibrin fragment E (FFE). This FFE antibody (Ab) induced significant growth inhibition of a human cancer xenograft in mice and suppression of tumour angiogenesis, leaving no formed vessels and only CD31-staining endothelial fragments in place. Tubule formation of HUVEC on MatrigelTM was also significantly inhibited by FFE Ab. Since MatrigelTM is fibrin-free, this effect implicated a different FFE Ab binding site than FFE. Flow cytometry of HUVEC showed that FFE Ab bound to HUVEC, but with a broad range of 55–98 %. Immunofluorescent staining of HUVEC explained this range, since FFE Ab was seen not to bind to human umbilical vein endothelial cells (HUVEC) directly but instead to a matrix protein variably adherent to HUVEC. This protein was identified as fibronectin (FN) by appearance, staining with FN Ab, and by a FN knockdown study. Neither HUVEC nor matrix reacted with fibrin D-dimer (DD) Ab. Immunofluorescent stains of HUVEC matrix with FFE and FN Ab’s showed that these Ab’s bound to the same epitopes on FN, as also seen on Western blots of purified FN. These findings indicate the presence of an antigenic determinant in fibrinogen/FFE that is homologous with an epitope(s) in FN recognised by FFE Ab, and critical for angiogenesis in this xenograft. The FN epitope(s) remains to be identified, but the present findings can be used for the selection of the appropriate clones from mice immunised with fibrinogen which can facilitate this identification, and which may also be of clinical use.

Keywords

Fibrin fragment E (FFE) - FFE antibody - fibronectin - angiogenesis

• References

• 1 Schlager SI, Dray S. Complete local tumour regression with antibody to fibrin fragment E. J Immunol 1975; 115: 976-981.
• 2 Christensen U. C-terminal lysine residues of fibrinogen fragments essential for binding to plasminogen. FEBS 1985; 182: 43-46.
• 3 Husain SS, Gurewich V, Lipinski B. Purification of a new high MW single chain form of urokinase (UK) from urine. Thromb Haemost 1981; 46: 11.
• 4 Liu J-N, Gurewich V. Fragment E-2 from fibrin substantially enhances pro-urokinase-induced glu-plasminogen activation. A kinetic study using a plas-min-resistant mutant pro-urokinase (Ala-158-rpro-UK). Biochemistry 1992; 31: 6311-6317.
• 5 Fleury V, Lijnen HR, Angles-Cano E. Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fi-brinolysis. J Biol Chem 1993; 268: 18554-18559.
• 6 Liu J-N, Gurewich V. A comparative study of the promotion of tissue plasmi-nogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin. J Clin Invest 1991; 88: 2012-2017.
• 7 Plow EF, Ploplis VA, Carmeliet P. et al. Plasminogen and cell migration in vivo. Fibrinol Proteol 1999; 13: 49-53.
• 8 Pepper MS. Role of the matrix metalloproteinase and plasminogen activator -plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001; 21: 1104-1117.
• 9 Andreasen PA, Kjoller L, Christensen L. et al. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 1997; 72: 1-22.
• 10 Pepper MS, Vassalli JD, Montesano R. et al. Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells. J Cell Biol 1987; 105: 2535-2541.
• 11 Folkman J. Tumour angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
• 12 Vassalli JD, Bellin D. Amiloride selectively inhibits the urokinase-type plasmi-nogen activator. FEBS Lett 1987; 214: 1870191.
• 13 Buttke TM, McCubrey JA, Owen TC. Use of an aqueous soluble tetrazolium/ formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. J Immunol Methods 1993; 157: 233-240.
• 14 Magnusson MK, Mosher DF. Fibronectin. Structure, assembly, and cardiovascular implications. Arterioscler Thromb Vasc Biol 1998; 18: 1363-1370.
• 15 George EL, Baldwin HS, Hynes RO. Fibronectins are essential for heart and blood vessel morphogenesis but are dispensable for initial specification of precursor cells. Blood 1997; 90: 3073-3078.
• 16 Astrof S, Crowley D, Hynes RO. Multiple cardiovascur defects caused by the absence of alternatively spliced segments of fibronectin. Dev Biol 2007; 311: 11-24.
• 17 Astrof S, Hynes RO. Fibrinonectins in vascular morphogenesis. Angiogenesis 2009; 12: 165-175.
• 18 Khan ZA, Chan BM, Uniyal S. et al. EDB fibronectin and angiogenesis-a novel mechanistic pathway. Angiogenesis 2005; 08: 183-196.
• 19 Menrad A, Menssen HD. ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin Ther Targets 2005; 09: 491-500.
• 20 Wahl O, Oswald M, Tretzel L. et al. Inhibition of tumour angiogenesis by antibodies, synthetic small molecules and natural products. Curr Med Chem 2011; 18: 3136-3155.
• 21 Gilbert MR, Dignam JJ, Armstrong TS. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014; 370: 699-708.
• 22 Fuchs CS, Tomasek J, Yong CJ. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383: 31-39.
• 23 Schmidt-Erfurth U, Pollreisz A, Mitsch C. et al. Antivascular endothelial growth factors in age-related macular degeneration. Dev Ophthalmol 2010; 46: 21-38.
• 24 Goto F, Goto K, Weindel K. et al. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest 1993; 69: 508-517.